Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quest Diagnostics ( (DGX) ) has issued an announcement.
On February 10, 2026, Quest Diagnostics reported that fourth-quarter 2025 revenue rose 7.1% year-on-year to $2.81 billion and full-year revenue increased 11.8% to $11.04 billion, with full-year diluted EPS up 13.8% to $8.75 and cash from operations reaching $1.89 billion. The Board also authorized an additional $1 billion share repurchase and raised the quarterly dividend 7.5% to $0.86 per share, effective for the dividend payable on April 20, 2026 to shareholders of record on April 6, 2026.
Management highlighted double-digit growth in 2025 as evidence of successful execution in clinical innovation, consumer testing, operational efficiency, and strategic collaborations, including major agreements with Corewell Health, Epic, and Google Cloud. For 2026, Quest guided revenues to $11.70 billion–$11.82 billion and reported diluted EPS to $9.45–$9.65, signaling confidence in sustained growth while it invests in AI, automation, and advanced diagnostics such as Alzheimer’s and cancer testing.
The most recent analyst rating on (DGX) stock is a Buy with a $210.00 price target. To see the full list of analyst forecasts on Quest Diagnostics stock, see the DGX Stock Forecast page.
Spark’s Take on DGX Stock
According to Spark, TipRanks’ AI Analyst, DGX is a Neutral.
Overall score reflects strong financial performance and an upbeat earnings outlook with raised guidance, partially offset by mixed technical momentum (negative MACD and trading below key mid-term averages) and a moderate valuation profile (P/E ~20.5 with a ~1.8% yield).
To see Spark’s full report on DGX stock, click here.
More about Quest Diagnostics
Quest Diagnostics Inc., based in Secaucus, N.J., is a leading provider of diagnostic information services, generating most of its revenues from clinical laboratory testing for clinicians, health systems, and consumers. The company is expanding geographically, including into Canada, and is deepening its role in wellness, advanced diagnostics, and technology-enabled lab services through collaborations with health systems, tech firms, and consumer wellness brands.
Average Trading Volume: 1,048,785
Technical Sentiment Signal: Buy
Current Market Cap: $21.22B
For a thorough assessment of DGX stock, go to TipRanks’ Stock Analysis page.